L
Laura Massa
Researcher at University of Trieste
Publications - 20
Citations - 256
Laura Massa is an academic researcher from University of Trieste. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 6, co-authored 15 publications receiving 175 citations.
Papers
More filters
Journal ArticleDOI
Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease
Eugenio Picano,Quirino Ciampi,Rodolfo Citro,Antonello D'Andrea,Maria Chiara Scali,Lauro Cortigiani,Iacopo Olivotto,Fabio Mori,Maurizio Galderisi,Marco Fabio Costantino,Lorenza Pratali,Giovanni Di Salvo,Eduardo Bossone,Francesco Ferrara,Luna Gargani,Fausto Rigo,Nicola Gaibazzi,Giuseppe Limongelli,Giuseppe Pacileo,Maria Grazia Andreassi,Bruno Pinamonti,Laura Massa,Marco Antonio Rodrigues Torres,Marcelo Haertel Miglioranza,Clarissa Borguezan Daros,José Luis de Castro e Silva Pretto,Branko Beleslin,Ana Djordjevic-Dikic,Albert Varga,Attila Pálinkás,Gergely Ágoston,Dario Gregori,Paolo Trambaiolo,Sergio Severino,Ayana Arystan,Marco Paterni,Clara Carpeggiani,Paolo Colonna +37 more
TL;DR: The study will create the cultural, informatic and scientific infrastructure connecting high-volume, accredited SE labs, sharing common criteria of indication, execution, reporting and image storage of SE to obtain original safety, feasibility, and outcome data in evidence-poor diagnostic fields, also outside the established core application of SE in CAD based on regional wall motion abnormalities.
Journal ArticleDOI
Cardiac Tumors: Diagnosis, Prognosis, and Treatment
Rossana Bussani,Matteo Castrichini,Luca Restivo,Enrico Fabris,Aldostefano Porcari,Federico Ferro,Alberto Pivetta,Renata Korcova,Chiara Cappelletto,Paolo Manca,Vincenzo Nuzzi,Riccardo Bessi,Linda Pagura,Laura Massa,Gianfranco Sinagra +14 more
TL;DR: A comprehensive clinical and multimodality imaging evaluation of cardiac tumors is fundamental to obtain a proper differential diagnosis, but histopathology is necessary to reach the final diagnosis and subsequent clinical management.
Journal ArticleDOI
Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis.
Michele Moretti,Alessandra Buiatti,Marco Merlo,Laura Massa,Enrico Fabris,Bruno Pinamonti,Gianfranco Sinagra +6 more
TL;DR: In this paper, a series of clinical cases of pericarditis refractory to conventional treatment was analyzed, where high-dose intravenous human immunoglobulins (IvIgs) were used as a treatment option.
Journal ArticleDOI
Quality control of regional wall motion analysis in stress Echo 2020
Quirino Ciampi,Eugenio Picano,Marco Paterni,Clarissa Borguezan Daros,Iana Simova,José Luis de Castro e Silva Pretto,Maria Chiara Scali,Nicola Gaibazzi,Sergio Severino,Ana Djordjevic-Dikic,Jarosław D. Kasprzak,Angela Zagatina,Albert Varga,Jorge Lowenstein,Pablo Merlo,Miguel Amor,Jelena Celutkiene,Julio E. Pérez,Giovanni Di Salvo,Maurizio Galderisi,Fabio Mori,Marco Fabio Costantino,Laura Massa,Milica Dekleva,Daniel Quesada Chaves,Paolo Trambaiolo,Rodolfo Citro,Paolo Colonna,Fausto Rigo,Marco Antonio Rodrigues Torres,Ines Monte,Ivan Stankovic,Aleksander Neskovic,Lauro Cortigiani,Federica Re,Claudio Dodi,Antonello D'Andrea,Bruno Villari,Ayana Arystan,Michele De Nes,Clara Carpeggiani +40 more
TL;DR: In SE reading, the volume of activity or years of experience is not synonymous with diagnostic quality, and Qualitative analysis and operator-dependence can become a limiting weakness in clinical practice, in the absence of strict pathways of learning, credentialing and audit.
Journal ArticleDOI
Comparison of Patient Characteristics and Course of Hypertensive Hypokinetic Cardiomyopathy Versus Idiopathic Dilated Cardiomyopathy.
Marco Bobbo,Bruno Pinamonti,Marco Merlo,Davide Stolfo,Annamaria Iorio,Federica Ramani,Giulia Barbati,Cosimo Carriere,Laura Massa,Stefano Poli,Sara Scapol,Marta Gigli,Andrea Di Lenarda,Gianfranco Sinagra +13 more
TL;DR: HHC has a high prevalence among patients with "idiopathic" LV dysfunction, and the natural history of patients with HHC is characterized by a rapid response to optimal therapy for heart failure, a favorable cardiovascular outcome, and a relevant incidence of noncardiovascular events.